Juloori Aditya, Shah Chirag, Stephans Kevin, Vassil Andrew, Tendulkar Rahul
Cleveland Clinic, Taussig Cancer Institute, Department of Radiation Oncology, Cleveland, OH, USA.
Cleveland Clinic, Taussig Cancer Institute, Department of Radiation Oncology, Strongsville, OH, USA.
Prostate Cancer. 2016;2016:2420786. doi: 10.1155/2016/2420786. Epub 2016 May 23.
High-risk prostate cancer is an aggressive form of the disease with an increased risk of distant metastasis and subsequent mortality. Multiple randomized trials have established that the combination of radiation therapy and long-term androgen deprivation therapy improves overall survival compared to either treatment alone. Standard of care for men with high-risk prostate cancer in the modern setting is dose-escalated radiotherapy along with 2-3 years of androgen deprivation therapy (ADT). There are research efforts directed towards assessing the efficacy of shorter ADT duration. Current research has been focused on assessing hypofractionated and stereotactic body radiation therapy (SBRT) techniques. Ongoing randomized trials will help assess the utility of pelvic lymph node irradiation. Research is also focused on multimodality therapy with addition of a brachytherapy boost to external beam radiation to help improve outcomes in men with high-risk prostate cancer.
高危前列腺癌是一种侵袭性疾病，远处转移风险和后续死亡率增加。多项随机试验已证实，与单独使用任何一种治疗方法相比，放射治疗与长期雄激素剥夺治疗相结合可提高总生存率。现代环境下高危前列腺癌男性的标准治疗是剂量递增放疗以及2至3年的雄激素剥夺治疗（ADT）。目前有研究致力于评估更短ADT疗程的疗效。当前的研究集中在评估大分割和立体定向体部放射治疗（SBRT）技术。正在进行的随机试验将有助于评估盆腔淋巴结照射的效用。研究还集中在多模式治疗，即在体外束放射治疗中增加近距离放射治疗增强剂量，以帮助改善高危前列腺癌男性的治疗效果。
